FDA Advisory Panel Votes to Recommend BPC-157, TB-500, KPV, and MOTS-c for Compounding (2026)
By RUOcodes.com Research Team
Published: · Updated: Sep 6, 2026
FDA advisory panel voted 8-6 to recommend BPC-157, TB-500, KPV, and MOTS-c for 503A compounding. What the July 2026 decision actually means.
FDA advisory panel vote coverage for BPC-157, TB-500, KPV, and MOTS-c. Now that the votes are in, the next question is what actually happens next and when. For the complete five-step road map from advisory recommendation to legal compounding access — including the realistic 2027–2028 timeline and the Category 1 wildcard — read The FDA Voted. Now What? The Complete Regulatory Road Map After the PCAC Peptide Decision . For research and educational purposes only. Not medical advice. UPDATED: July 24, 2026. Day 2 votes on Semax , Epitalon , and Emideltide are occurring today as this post is published. We will update with final results as they become available. TL;DR: What Just Happened at the FDA PCAC Meeting The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend BPC-157, KPV , TB-500 , and MOTS-c for inclusion on the 503A Bulk Drug Substances List, meaning licensed compounding pharmacies could eventually prepare these compounds for patients with valid prescriptions. The votes were close. The recommendations are non-binding. The FDA makes the final call. Even if the FDA agrees, a formal rulemaking process must follow, and that typically takes 6 to 18 months. Nothing changes at your pharmacy tomorrow. But this is the most significant regulatory development in the peptide space in years, and it matters. July 2026 PCAC Vote Results at a Glance Compound Day Vote Indication Evaluated Human Trial Data BPC-157 Day 1 (July 23) 8–6 In Favor Wound healing, gastrointestinal 3 small human studies KPV Day 1 (July 23) 8–6 In Favor Inflammatory conditions, ulcerative colitis None published TB-500 Day 1 (July 23) 8–6 In Favor Wound healing, tissue repair None published MOTS-c Day 1 (July 23) 7–5 In Favor Obesity-related metabolic applications None published Semax Day 2 (July 24) Pending Cerebral ischemia Russian clinical data Epitalon Day 2 (July 24) Pending Healthy aging, osteoporosis Russian cohort studies Emideltide (DSI…
← Back to Blog